Structure of Pacritinib
CAS No.: 937272-79-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50 = 23 nM) and the JAK2V617F mutant (IC50 = 19 nM), and also inhibits FLT3 (IC50 = 22 nM) and its mutant FLT3D835Y (IC50 = 6 nM).
Synonyms: SB1518
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 937272-79-2 |
Formula : | C28H32N4O3 |
M.W : | 472.58 |
SMILES Code : | C1(OCCN2CCCC2)=CC=C(/N=C3NC4=CC=N\3)C=C1COC/C=C/COCC5=CC4=CC=C5 |
Synonyms : |
SB1518
|
MDL No. : | MFCD22572772 |
InChI Key : | HWXVIOGONBBTBY-ONEGZZNKSA-N |
Pubchem ID : | 46216796 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H317 |
Precautionary Statements: | P280 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
Hepatic Stellate Cells (HSCs) | 1 μm | 24 h | Pacritinib reduced gene expression of fibrosis markers and decreased proliferation and contraction of HSCs. | PMC10026969 |
breast cancer cell lines | 50 mg/kg | various times | Pacritinib reduced cell viability and promoted apoptosis in breast cancer cells. | PMC11533721 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | CCl4 and ethanol-induced liver fibrosis | Oral | 300 mg/kg | three times per week for 3 weeks | Pacritinib treatment reduced liver fibrosis and liver injury. | PMC10026969 |
Mice | TNBC PDX model | Oral | 50 mg/kg | twice daily for 5 days/week until study termination | Pacritinib effectively suppressed tumor growth in vivo. | PMC11533721 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02251821 | Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less << | Phase 2 | Recruiting | - | United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit 206-667-1317 rsalit@fredhutch.org Principal Investigator: Rachel B. Salit Less << |
NCT02823171 | Healthy | Phase 1 | Completed | - | United States, Indiana ... More >> Covance Clinical Research Unit Inc. Evansville, Indiana, United States, 47710 Less << |
NCT02342353 | Non-Small Cell Lung Cancer ... More >> Nonsmall Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Less << | Phase 1 | Terminated(Drug shortage) | - | United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less << |
NCT02807207 | Healthy Subjects | Phase 1 | Completed | - | United States, Indiana ... More >> Covance Clinical Research Unit Inc. Evansville, Indiana, United States, 47710 Less << |
NCT02584777 | Primary Myelofibrosis | Phase 2 | Withdrawn | August 2020 | - |
NCT02808455 | Healthy Subjects | Phase 1 | Completed | - | United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less << |
NCT02891603 | Graft Vs Host Disease ... More >> GVHD Less << | Phase 1 Phase 2 | Recruiting | June 2020 | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Principal Investigator: Joseph Pidala, M.D. Sub-Investigator: Melissa Alsina, M.D. Sub-Investigator: Marco Davila, M.D., Ph.D. Sub-Investigator: Linda Kelley, Ph.D. Sub-Investigator: Farhad Khimani, M.D. Sub-Investigator: Frederick Locke, M.D. Sub-Investigator: Asmita Mishra, M.D. Sub-Investigator: Taiga Nishihori, M.D. Sub-Investigator: Jose Ochoa-Bayona, M.D. Sub-Investigator: Lia Perez, M.D. Sub-Investigator: Hugo Fernandez, M.D, Less << |
NCT02469415 | Leukemia | Phase 2 | Terminated(FDA Clinical Hold) | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02323607 | Recurrent Adult Acute Myeloid ... More >>Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << | Phase 1 | Suspended(internal data analys... More >>is) Less << | September 30, 2018 | United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less << |
NCT02469415 | - | Terminated(FDA Clinical Hold) | - | - | |
NCT02410551 | - | Terminated | - | - | |
NCT02410551 | Myeloproliferative Diseases | Phase 2 | Terminated | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02807077 | Myelofibrosis | PHASE1 | COMPLETED | 2025-07-15 | APEX GmbH, Munich, D-81241, Ge... More >>rmany|Republican Clinical Hospital, Chisinau, MD-2025, Moldova, Republic of|Carol Davila Nephrology Hospital Bucharest, Bucharest, Romania Less << |
NCT02277093 | Colorectal Cancer | PHASE2 | TERMINATED | 2016-10-27 | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << |
NCT02564536 | Chronic Myelomonocytic Leukemi... More >>a Juvenile Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic Syndromes Myelofibrosis Less << | Phase 1 | Withdrawn(Lack of funding foll... More >>owing full FDA clinical hold) Less << | June 30, 2020 | - |
NCT03165734 | Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << | Phase 2 | Recruiting | March 1, 2019 | - |
NCT03601819 | Lymphoma, T-Cell, Cutaneous|Ly... More >>mphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma Less << | PHASE1 | TERMINATED | 2020-07-17 | University of Michigan Rogel C... More >>ancer Center, Ann Arbor, Michigan, 48109, United States Less << |
NCT01773187 | Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << | Phase 3 | Terminated | - | - |
NCT02807051 | Drug Interaction Study | Phase 1 | Completed | - | United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less << |
NCT02055781 | Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << | Phase 3 | Terminated | - | - |
NCT02277093 | Colorectal Cancer | PHASE2 | TERMINATED | 2016-10-27 | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << |
NCT02807116 | Healthy Subjects | Phase 1 | Completed | - | United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less << |
NCT02677948 | Chronic Lymphocytic Leukemia ... More >> Lymphoma, Small Lymphocytic Less << | Phase 1 Phase 2 | Withdrawn(FDA has placed all t... More >>rials involving Pacritinib on Full Clinical Hold) Less << | October 2018 | United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT02532010 | Acute Myeloid Leukemia (AML) | Phase 2 | Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << | - | United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10021 Less << |
NCT03645824 | Myelofibrosis | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-02-27 | BE-Antwerpen-ZNASTUIVENBERG, A... More >>ntwerpen, Belgium|BE-Gent-UZGENT, Gent, Belgium|BE-Leuven-UZLEUVEN, Leuven, Belgium|BE-Roeselare-AZDELTA, Roeselare, Belgium|NL-Amsterdam-AMC, Amsterdam, Netherlands|NL-Amsterdam-VUMC, Amsterdam, Netherlands|NL-Groningen-UMCG, Groningen, Netherlands|NL-Maastricht-MUMC, Maastricht, Netherlands|NL-Nijmegen-RADBOUDUMC, Nijmegen, Netherlands|NL-Rotterdam-EMCDANIEL, Rotterdam, Netherlands|NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands|NL-Utrecht-UMCUTRECHT, Utrecht, Netherlands Less << |
NCT02765724 | Myelofibrosis | PHASE1 | COMPLETED | 2025-06-15 | APEX GmbH, Munich, D-81241, Ge... More >>rmany|Republican Clinical Hospital, Chisinau, MD-2025, Moldova, Republic of Less << |
NCT02532010 | - | Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << | - | - | |
NCT02803762 | Healthy | PHASE1 | COMPLETED | 2025-10-14 | QPS Netherlands B.V., Groninge... More >>n, 9713 GZ, Netherlands Less << |
NCT05531786 | Graft vs Host Disease | PHASE1|PHASE2 | RECRUITING | 2025-07-22 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT04884191 | Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post- Essential Thrombocythemia Myelofibrosis Less << | PHASE2 | COMPLETED | 2019-09-04 | Mayo Clinic Hospital, Phoenix,... More >> Arizona, 85054, United States|City of Hope, Duarte, California, 91010, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|Yale School of Medicine, New Haven, Connecticut, 06520, United States|Medical Faculty Associates, Inc., Washington, District of Columbia, 20037, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists & Research Institute, West Palm Beach, Florida, 33401, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, United States|The University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Ochsner Medical Center, New Orleans, Louisiana, 70121, United States|Saint Agnes Hospital, Baltimore, Maryland, 21229, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Weill Cornell Medical College, New York, New York, 10021, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|University of Rochester, Rochester, New York, 14642, United States|Duke University Hospital, Durham, North Carolina, 27710, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, Texas, 78229, United States|University of Utah School of Medicine, Salt Lake City, Utah, 84112, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|CHU Hopital Sud, Amiens, 80054, France|Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille Cedex, 59037, France|CHU de Nimes - Hopital Universitaire Caremeau, N?mes, 30029, France|H?pital Saint-Louis, Paris, 75010, France|CHU Hopitaux de Bordeaux - H?pital Haut-Lévêque, Pessac, 33604, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, 69495, France|Centre Hospitalier Universitaire de Toulouse- H?pital Purpan, Toulouse Cedex, 31059, France|SE AOK I. sx. Belgyogyaszati Klinika, Budapest, 1083, Hungary|Debreceni Egyetem Klinikai K?zpont, Debrecen, 4032, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, 7400, Hungary|Azienda Ospedaliero-Universitaria Careggi, Firenze, 50134, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori, Meldola, 47014, Italy|ASST Monza - Ospedale San Gerardo, Monza, 20900, Italy|Yeungnam University Medical Center, Daegu, 42415, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Hospital del Mar, Barcelona, 08003, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Clínica Universidad de Navarra, Pamplona, 31008, Spain|Skane University Hospital Lund, Lund, 22185, Sweden|Orebro University Hospital, ?rebro, 70185, Sweden|Beatson West of Scotland Cancer Center, Glasgow, G12 0YN, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, E1 2ES, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, SE1 9RT, United Kingdom|Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, W12 0HS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, OX3 7LE, United Kingdom Less << |
NCT04635059 | Prostate Cancer | PHASE2 | TERMINATED | 2024-10-27 | Froedtert & the Medical Colleg... More >>e of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less << |
NCT06052618 | KSHV Inflammatory Cytokine Syn... More >>drome (KICS)|Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease Less << | PHASE2 | RECRUITING | 2034-01-01 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT04520269 | Breast Cancer | PHASE1|PHASE2 | UNKNOWN | 2025-07-23 | National University Hospital, ... More >>Singapore, Singapore Less << |
NCT01436084 | Leukemia | PHASE2 | TERMINATED | 2025-06-13 | UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less << |
NCT01263899 | Hodgkin Lymphoma|Mantle Cell L... More >>ymphoma|Indolent Lymphoma Less << | PHASE2 | COMPLETED | 2025-02-12 | University of Nebraska Medical... More >> Center, Omaha, Nebraska, 68198, United States|Weill Medical College of Cornell, New York, New York, 10021, United States|University of Rochester James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|MD Anderson Cancer Canter, Houston, Texas, 77030, United States|University of British Columbia, Vancouver, British Columbia, V5Z 4E6, Canada Less << |
NCT00719836 | Acute Myelogenous Leukemia|Chr... More >>onic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Myelofibrosis Less << | PHASE1|PHASE2 | COMPLETED | 2025-01-12 | The University of Chicago Hosp... More >>itals, Chicago, Illinois, 60637, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States Less << |
NCT00741871 | Lymphoma, Malignant|Hodgkin's ... More >>Lymphoma|B Cell Lymphoma Less << | PHASE1 | COMPLETED | 2025-10-11 | MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less << |
NCT06538181 | E1 Ubiqutin-activating Enzyme,... More >> X-linked, Autoinflammatory, Somatic Syndrome|VEXAS|Vexas Syndrome Less << | PHASE1 | NOT_YET_RECRUITING | 2029-03-31 | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << |
NCT04858256 | T-Cell Neoplasm|Lymphoprolifer... More >>ative Disorders Less << | PHASE2 | RECRUITING | 2025-11-28 | City of Hope, Duarte, Californ... More >>ia, 91010, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43202, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States Less << |
NCT00745550 | Myelofibrosis|Myeloproliferati... More >>ve Disorders|Polycythemia Vera|Essential Thrombocythemia Less << | PHASE1|PHASE2 | COMPLETED | 2025-01-12 | Mayo Clinic, Scottsdale, Arizo... More >>na, 85259, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3002, Australia|Royal Melbourne Hospital, Melbourne, Victoria, 3050, Australia|Royal Adelaide Hospital, Adelaide, 5000, Australia Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.12mL 0.42mL 0.21mL |
10.58mL 2.12mL 1.06mL |
21.16mL 4.23mL 2.12mL |